JP5411847B2 - Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形 - Google Patents

Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形 Download PDF

Info

Publication number
JP5411847B2
JP5411847B2 JP2010506227A JP2010506227A JP5411847B2 JP 5411847 B2 JP5411847 B2 JP 5411847B2 JP 2010506227 A JP2010506227 A JP 2010506227A JP 2010506227 A JP2010506227 A JP 2010506227A JP 5411847 B2 JP5411847 B2 JP 5411847B2
Authority
JP
Japan
Prior art keywords
anticancer
compound
cancer
salt
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010506227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010525057A (ja
JP2010525057A5 (enExample
Inventor
雅史 川崎
裕夫 水野
俊浩 坂本
公正 鈴木
マキューン，アーリーン，イー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Merck Sharp & Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme LLC filed Critical Merck Sharp & Dohme LLC
Priority to JP2010506227A priority Critical patent/JP5411847B2/ja
Publication of JP2010525057A publication Critical patent/JP2010525057A/ja
Publication of JP2010525057A5 publication Critical patent/JP2010525057A5/ja
Application granted granted Critical
Publication of JP5411847B2 publication Critical patent/JP5411847B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010506227A 2007-04-25 2008-04-22 Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形 Active JP5411847B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010506227A JP5411847B2 (ja) 2007-04-25 2008-04-22 Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2007115448 2007-04-25
JP2007115448 2007-04-25
US18507P 2007-10-24 2007-10-24
US61/000,185 2007-10-24
JP2010506227A JP5411847B2 (ja) 2007-04-25 2008-04-22 Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形
PCT/US2008/005155 WO2008133866A1 (en) 2007-04-25 2008-04-22 Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor

Publications (3)

Publication Number Publication Date
JP2010525057A JP2010525057A (ja) 2010-07-22
JP2010525057A5 JP2010525057A5 (enExample) 2011-06-30
JP5411847B2 true JP5411847B2 (ja) 2014-02-12

Family

ID=39579886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010506227A Active JP5411847B2 (ja) 2007-04-25 2008-04-22 Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形

Country Status (4)

Country Link
US (1) US8198281B2 (enExample)
EP (1) EP2155752B1 (enExample)
JP (1) JP5411847B2 (enExample)
WO (1) WO2008133866A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140821T1 (hr) * 2009-09-15 2014-10-10 Merck Sharp & Dohme Corp. Priprema kristalnih hemihidratnih oblika dihidropirazolopirimidinona
CN102311443B (zh) * 2011-08-24 2014-07-16 上海北卡医药技术有限公司 盐酸伊立替康的新晶型及其制备方法
US9345705B2 (en) 2011-09-15 2016-05-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
SMT201700595T1 (it) 2012-11-28 2018-03-08 Merck Sharp & Dohme Composizioni e metodi per trattare il cancro
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
JP2015214524A (ja) * 2014-05-13 2015-12-03 国立大学法人鳥取大学 増感剤、抗がん剤、および超音波を用いたがん治療
JP6871255B2 (ja) * 2015-12-30 2021-05-12 シントン・ベスローテン・フェンノートシャップ ゲフィチニブの結晶形ａを製造する方法
EP3411039B1 (en) 2016-02-02 2020-06-24 The Regents of The University of Michigan Mercaptopurine hemihydrate
GB201612092D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
JP6717457B2 (ja) 2017-01-23 2020-07-01 シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド Ｗｅｅ１阻害剤としての１，２−ジヒドロ−３Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−３−オン誘導体
EP3712150B1 (en) 2017-11-01 2024-06-12 Wuxi Biocity Biopharmaceutics Co., Ltd. Macrocyclic compound serving as wee1 inhibitor and applications thereof
US11479555B2 (en) 2018-02-23 2022-10-25 Newave Pharmaceutical Inc. Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase
WO2020069105A1 (en) * 2018-09-27 2020-04-02 Dana-Farber Cancer Institute, Inc. Degraders of wee1 kinase
JP7481336B2 (ja) 2018-10-26 2024-05-10 ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド Ｗｅｅ１阻害剤としてのピリミドピラゾロン類誘導体及びその使用
CN113614087B (zh) * 2019-03-22 2023-06-02 首药控股(北京)股份有限公司 Wee1抑制剂及其制备和用途
LT3964510T (lt) 2019-04-30 2024-08-12 Wuxi Biocity Biopharmaceutics Co., Ltd. Wee1 inhibitorinio junginio kristalinė forma ir jos panaudojimas
IL292348A (en) 2019-10-25 2022-06-01 Astrazeneca Ab Cancer treatment methods
EP4069224A4 (en) * 2019-12-20 2023-12-20 Recurium IP Holdings, LLC ASSOCIATIONS
CN115023229A (zh) * 2019-12-20 2022-09-06 里科瑞尔姆Ip控股有限责任公司 组合
AU2021290701A1 (en) 2020-06-17 2023-02-02 Wigen Biomedicine Technology (shanghai) Co., Ltd. Pyrazolo(3,4-d)pyrimidine-3-ketone derivative as Wee-1 inhibitor
CN117396480B (zh) * 2021-03-26 2026-07-31 奥弗恩制药公司 吡唑并嘧啶酮化合物
EP4332104A4 (en) 2021-04-30 2025-04-16 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Fused ring compound as a WEE-1 inhibitor, as well as production process and use thereof
CN113735863A (zh) * 2021-09-29 2021-12-03 武汉九州钰民医药科技有限公司 Wee1抑制剂adavosertib的制备工艺
CN116462687B (zh) 2022-01-18 2025-01-07 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN117402162A (zh) 2022-07-13 2024-01-16 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003224341A1 (en) * 2002-04-26 2003-11-10 Warner-Lambert Company Llc Inhibitors of checkpoint kinases (wee1 and chk1)
PE20080695A1 (es) * 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel

Also Published As

Publication number Publication date
EP2155752A1 (en) 2010-02-24
EP2155752B1 (en) 2018-09-19
JP2010525057A (ja) 2010-07-22
WO2008133866A1 (en) 2008-11-06
US8198281B2 (en) 2012-06-12
US20100124544A1 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
US8198281B2 (en) Crystalline forms of dihydropyrazolopyrimidinone
US8507504B2 (en) Process for producing bicycloaniline derivatives
EP2016080B1 (en) Dihydropyrazolopyrimidinone derivatives
EP2213673B1 (en) Pyridone-substituted-dihydropyrazolopyrimidinone derivative
EP2168966B1 (en) Bicycloaniline derivative
EP2411010B1 (en) Novel aminopyridine derivatives having aurora a selective inhibitory action
KR20070072562A (ko) 오로라 ａ 선택적 억제 활성을 갖는 신규한 아미노피리딘유도체
US8367690B2 (en) Aminopyridine derivatives having aurora a selective inhibitory action
US8263632B2 (en) Aminopyridine derivatives having Aurora A selective inhibitory action
ES2702698T3 (es) Polimorfo del derivado de dihidropirazolopirimidinona como inhibidor de la cinasa Wee1
EP4401781A1 (en) Methods of cancer treatment using a combination of btk inhibitors and pi3 kinase inhibitors

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20101210

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20110107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110418

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120221

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120321

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20130223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130517

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130920

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131108

R150 Certificate of patent or registration of utility model

Ref document number: 5411847

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250